Dosage Charts Calculator Blends & Stacks Learn Blog Peptides
Open Calculator
Blog  ›  Melanotan II vs PT-141: Simple Research Comparison Guide

Melanotan II vs PT-141: Simple Research Comparison Guide

Jun 11, 2026 4 min Other
TL;DR
Melanotan II and PT-141 are both melanocortin peptides studied for pigmentation and sexual function, but they differ in selectivity and safety profile. PT-141 (bremelanotide) has advanced further in clinical trials. Neither is approved for self-use, and both carry documented risks.

Two Peptides, One Confusing Family Tree

Melanotan II and PT-141 are synthetic cousins. Both are lab-made versions of a natural hormone called alpha-melanocyte-stimulating hormone (α-MSH). That hormone tells your body to make pigment, regulate appetite, and — yes — influence sexual arousal. Researchers got curious and started tweaking its structure. Two notable results came out of that work: Melanotan II and PT-141.

They look similar on paper. In practice, they behave quite differently. Here's what the science says.

What Is Melanotan II?

Melanotan II (MT-II) is a non-selective melanocortin receptor agonist. "Non-selective" means it activates several receptor subtypes at once — MC1R, MC3R, MC4R, and MC5R. Think of it as a key that opens multiple locks. Researchers originally studied it for skin tanning and erectile function.Melanotan II

Online use of MT-II grew rapidly, driven by forums where people shared unregulated, internet-sourced vials.[6] A 2009 BMJ report flagged widespread unsupervised use in the general public — well before safety data was solid.[5]

More recently, a 2023 animal study found that MT-II reversed memory problems caused by a high-fat diet in zebrafish — a surprising new angle that hints at neurological research potential.[3] But the risks are real too. A published case report linked MT-II use to a serious kidney event called renal infarction, where blood flow to the kidney is suddenly blocked.[4]

What Is PT-141?

PT-141 — now better known by its clinical name bremelanotide — is a more refined version. Scientists modified the MT-II structure to make it more selective and better suited for clinical use. It was developed as a nasal spray to treat erectile dysfunction (ED) and female sexual dysfunction (FSD).[1]

It completed Phase IIb trials for ED back in 2003 and was on the path to Phase III shortly after.[1] Bremelanotide eventually won FDA approval for hypoactive sexual desire disorder (HSDD) in women under the brand name Vyleesi — though the approved route is subcutaneous injection, not nasal.[2]

Because PT-141 has a clinical track record, its research dosing is better characterized. You can explore that data on the PT-141 dosing chart.

Quick Comparison: MT-II vs PT-141

  • Receptor selectivity: MT-II hits multiple receptors; PT-141 is more targeted
  • Primary research focus: MT-II → tanning, appetite, cognition; PT-141 → sexual dysfunction
  • Clinical development: PT-141 reached FDA approval (as bremelanotide); MT-II has not
  • Documented risks: MT-II linked to renal events[4] and widespread unregulated use[5]; PT-141/bremelanotide has defined clinical safety monitoring[2]
  • Research dosing data: PT-141 more standardized; MT-II doses vary widely in forum reports[6]

How Research Dosing Differs

This is where things get nuanced. Because MT-II never completed formal clinical trials the same way PT-141 did, its "research doses" come from a patchwork of animal studies, early human trials, and — unfortunately — self-reported online use.[6] That's a much shakier foundation.

PT-141's dosing has been shaped by structured clinical trial data, giving researchers clearer benchmarks to work from.[1] The approved bremelanotide dose for HSDD is 1.75 mg injected subcutaneously, used as needed.[2]

If you want to explore either peptide's dosing chart in detail, our calculator can help you understand the numbers — always in an educational, research-only context.

How to Choose What to Read About

Ask yourself what research angle interests you most:

  • Interested in tanning or pigmentation research? Melanotan II has more literature on melanocortin receptor activation and skin effects. Start with the Melanotan II chart.
  • Interested in sexual function or clinical peptide research? PT-141/bremelanotide has the richer clinical trial record. The PT-141 chart is your starting point.
  • Interested in newer angles like cognition or metabolism? MT-II is seeing fresh preclinical research — like the zebrafish memory study — worth following.[3]

Neither peptide is approved for self-administration outside a clinical context. Both carry real risks. The goal here is to help you read smarter, not to recommend use.

The Bottom Line

Melanotan II is broader and less refined. PT-141 is more targeted and has genuine clinical trial history behind it. They share a family resemblance but are not interchangeable. Understanding the difference helps you navigate the research literature with much more confidence.

Sources

  1. PT-141 Palatin. — Current opinion in investigational drugs (London, England : 2000), 2004. PMID 15134289.
  2. Bremelanotide. — , 2006. PMID 31369224.
  3. Melanotan-II reverses memory impairment induced by a short-term HF diet. — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023. PMID 37478579.
  4. Melanotan II: a possible cause of renal infarction: review of the literature and case report. — CEN case reports, 2020. PMID 31953620.
  5. Use of melanotan I and II in the general population. — BMJ (Clinical research ed.), 2009. PMID 19224885.
  6. Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. — Dermatology (Basel, Switzerland), 2021. PMID 34464955.
See the dosage chart — Melanotan II
A melanocortin agonist researched for pigmentation and libido.
Melanotan II

FAQ

Are Melanotan II and PT-141 the same thing?
No, though they are chemically related. Both are synthetic analogs of alpha-MSH, a natural hormone. Melanotan II activates multiple melanocortin receptors non-selectively, while PT-141 (bremelanotide) is more targeted. PT-141 has completed clinical trials and received FDA approval for a specific condition; Melanotan II has not reached that stage.[1][5]
What has research found about Melanotan II risks?
Studies and case reports have flagged several concerns. A published case report linked Melanotan II use to renal infarction — a serious blockage of blood flow to the kidney.[4] A BMJ report also highlighted widespread unregulated use with little safety oversight.[5] Forum research confirmed users often rely on misinformation when dosing.[6]
What is PT-141 approved for clinically?
PT-141, under its clinical name bremelanotide (brand: Vyleesi), received FDA approval for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is administered as a subcutaneous injection before anticipated sexual activity. It was also studied extensively for erectile dysfunction in earlier clinical trials.[1][2]
Why does research dosing differ so much between the two peptides?
PT-141 has structured clinical trial data behind it, giving researchers clear, vetted dosing benchmarks.[1] Melanotan II never completed equivalent formal trials, so its reported research doses come from animal studies and self-reported forum use — a far less reliable source that makes standardization difficult.[6]
For research and educational use only. Not medical advice.